Developer docs
API playgroundTry for free, no card

Search company profiles

University Medicine Göttingen

Full company profile

uuid000hfnl

Namestring
University Medicine Göttingen
Legal namestring
Universitätsmedizin Göttingen
Websiteurl
umg.eu
Company typeenum
Private
Founded yearint
1732
Descriptiontext

Universitätsmedizin Göttingen (UMG) is a public university medical center in Göttingen, Lower Saxony, Germany, operating under the governance of Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts. Founded in 1732, UMG is the largest employer in southern Lower Saxony with approximately 7,900 staff, 1,600 beds across 61 clinics, institutes, and departments, and an annual patient volume of 55,000 inpatients and 270,000 outpatients. The institution operates as an integrated academic medical center combining three core missions — research, teaching, and patient care — and has added Transfer as a fourth strategic pillar under its UMGestalten 2032 strategy. Research focus areas include molecular cell biology, neuroscience, cardiovascular medicine, and oncology, with active collaborations including joint development of expansion microscopy with MIT (announced 2026-06-23) and a Phase I MVA-MERS-S vaccine trial with DZIF and CEPI (published in Nature Communications, 2026-01-26).

The technical platform spans clinical care, research infrastructure, and education. Notable proprietary capabilities include a privacy-preserving federated learning framework using pre-trained CT foundation models for multi-center lymph node metastasis detection in pancreatic cancer (2026-04-09), and the STÄPS simulation training center for medical education using standardized patients and OSCE examinations. The Studienzentrum provides IT, biometry, project management, and vigilance services to support clinical trials. Revenue is generated primarily through inpatient and outpatient care billed under the German DRG (Diagnosis Related Groups) system and statutory health insurance (GKV) frameworks, supplemented by research grants (Drittmittel), state subsidies, and teaching block funding. The go-to-market is direct-to-patient, with a recently formalized 'Ärzte & Zuweiser' (referring physicians) channel and regional patient transfer services. A major Neubau (new construction) project is currently underway as part of the UMGestalten 2032 modernization initiative, and the institution hosts the iSLS 2027 international conference.

Short descriptiontext

Universitätsmedizin Göttingen is a public university medical center combining patient care, biomedical research, and medical education across 61 clinics with 1,600 beds, serving 325,000 inpatients and outpatients annually in southern Lower Saxony, Germany.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersGöttingen, Germany
HQ citystring
Göttingen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
university medical center, inpatient healthcare services, medical research, clinical trials, medical education training
Industry2 codes
1Ambulatory Specialty Clinics (Multi-Specialty & Single-Specialty)
CodeHLAFABAAPrimaryYes
2Oncology & Cancer Specialty Hospitals
CodeHLAFAHACPrimaryNo
NAICS code2 codes
  • General Medical and Surgical Hospitals6221
  • Offices of Physicians62111
SIC code2 codes
  • Services-Hospitals8060
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
University Hospital and Academic Medical Center
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Hospital Services Revenue
TypeSubscription Recurring
Description

University medical center providing comprehensive healthcare services to patients, funded through statutory health insurance (GKV) and private insurance systems in Germany. Revenue generated from inpatient and outpatient medical treatments, procedures, and specialized clinical services.

umg.eu
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 5 records shown
1Medizincampus Wolfsburg (MCW)
Description

Medical campus location in Wolfsburg for medical education

umg.eu
+4 more records
Core offering1 text field

Universitätsmedizin Göttingen (UMG) operates as an academic medical center combining inpatient and outpatient clinical care, biomedical research, and medical education under a single institution. It runs 61 clinics, institutes, and departments with 1,600 beds, treating approximately 55,000 inpatients and 270,000 outpatients annually. Core clinical offerings include specialized treatments across oncology, cardiovascular medicine, neurosciences, and molecular cell biology, complemented by research focus areas and the STÄPS simulation-based medical training facility.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The Universitätsmedizin Göttingen (UMG) operates as an academic medical center combining clinical healthcare services, medical research, and education under one institution. The organization encompasses approximately 61 clinics, institutes, and departments with 1,600 beds, serving 55,000 inpatients and 270,000 outpatients annually. Key operational units include research focus areas (Molecular Cell Biology, Neuroscience, Cardiovascular Medicine, Oncology), a Studienzentrum (Study Center) providing IT, biometry, project management and vigilance services, and STÄPS as a dedicated simulation-based medical training facility.

Product and service6 records
1Inpatient Hospital Services
CategoryInpatient Healthcare Services
Description

Comprehensive inpatient medical care across 61 clinics, institutes, and departments with 1,600 beds, serving approximately 55,000 inpatients per year. Includes specialized treatment across oncology, cardiovascular medicine, neurosciences, and molecular cell biology.

2Outpatient Clinics and Ambulatory Care
CategoryOutpatient Healthcare Services
Description

Outpatient medical services including consultations, specialized ambulances (Sprechstunden), and ambulatory treatments serving approximately 270,000 outpatients per year.

3Emergency Medicine Services
CategoryEmergency Medical Services
Description

Emergency medical services including the ARDS/ECMO Center for intensive care and specialized emergency treatments for patients in southern Lower Saxony.

4STÄPS Medical Simulation Training
CategoryMedical Education and Training
Description

Student training center for medical practice and simulation where medical students practice clinical skills using simulated patients (Simulationspersonen) in role-play exercises and OSCE examinations (Objective Structured Clinical Examination).

5Clinical Trials and Research Services
CategoryClinical Research Services
Description

Clinical trial services including IT/prozessmanagement, biometry/datenmanagement, project management, vigilance, and on-site management/study secretariats provided through the Studienzentrum (Study Center).

6Medical Degree Programs
CategoryMedical Education
Description

Comprehensive medical education programs including the Medizincampus Wolfsburg (MCW) campus location for medical education, the Lehrhospital teaching hospital component, and continuing education programs.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Joint development of expansion microscopy technique that enlarges biological samples by 1,000-fold in each dimension. The technique enables amino acid visualization using conventional light microscopes, making high-resolution protein imaging more accessible without expensive cryo-EM or X-ray crystallography equipment.

2Multi-center Research Network
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Multi-center retrospective study on federated CT foundation models for privacy-preserving lymph node metastasis detection in pancreatic cancer, involving multiple institutions to improve diagnostic accuracy while protecting patient data.

nature.com
3German Center for Infection Research (DZIF)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-26
Description

DZIF conducted a phase I clinical trial for the MVA-MERS-S vaccine candidate showing stable and functional immune response persisting at least 24 months after vaccination. Study funded by DZIF and CEPI, published in Nature Communications. This represents a major pandemic preparedness research collaboration.

dzif.de
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Universitätsklinikum Freiburg
TypeDirect peer
Description

Multi-specialty German university hospital with a similar combination of oncology, cardiovascular, and neuroscience research priorities. Comparable academic medical center governance model under a public-law structure.

2Universitätsklinikum Köln
TypeDirect peer
Description

Large German university hospital of comparable scale (~1,500 beds) and research breadth. Direct comparable in size, public funding model, and translational research intensity.

3Universitätsklinikum Heidelberg
TypeDirect peer
Description

Major German university hospital with strong translational research and one of the country's leading oncology programs. Closely comparable to UMG in research intensity, NCI-style comprehensive cancer center positioning, and specialty research breadth.

TypeRegional player
Description

Comparable Swiss university hospital with multi-specialty academic medical center structure and translational research orientation. Operates in a different national healthcare system (Swiss DRG) but is structurally and functionally analogous to UMG.

TypeDirect peer
Description

German university hospital with notable oncology and transplant programs, comparable in academic structure and multi-specialty care delivery. Relevant reference for UMG's oncology and surgical specialty positioning.

TypeDirect peer
Description

Large multi-specialty academic medical center affiliated with Ludwig-Maximilians-Universität. Comparable to UMG in size, multi-specialty depth, and integration of research and patient care under a single university umbrella.

TypeDirect peer
Description

German university hospital with strong programs in oncology, neuroscience, and infectious disease, overlapping with UMG's research focus areas. Comparable academic medical center structure and translational research orientation.

TypeDirect peer
Description

Independent medical university with university hospital of comparable size to UMG (~1,500 beds). Comparable scale, regional role, and research focus areas, including transplantation and immunology.

TypeDirect peer
Description

Comparable-scale German university hospital (~1,700+ beds, ~10,000 staff) with research strengths in oncology, neuroscience, and cardiovascular medicine. Directly comparable operating model, bed count, and research portfolio to UMG.

TypeDirect peer
Description

Largest German university hospital with a comparable three-pillar model of research, teaching, and patient care. Operates at significantly larger scale (~3,000 beds) and is the most direct reference peer for UMG's academic medical center operating model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

University Medicine Göttingen

University Hospital and Academic Medical Centerumg.eu

Universitätsmedizin Göttingen is a public university medical center combining patient care, biomedical research, and medical education across 61 clinics with 1,600 beds, serving 325,000 inpatients and outpatients annually in southern Lower Saxony, Germany.

What University Medicine Göttingen does

Universitätsmedizin Göttingen (UMG) is a public university medical center in Göttingen, Lower Saxony, Germany, operating under the governance of Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts. Founded in 1732, UMG is the largest employer in southern Lower Saxony with approximately 7,900 staff, 1,600 beds across 61 clinics, institutes, and departments, and an annual patient volume of 55,000 inpatients and 270,000 outpatients. The institution operates as an integrated academic medical center combining three core missions — research, teaching, and patient care — and has added Transfer as a fourth strategic pillar under its UMGestalten 2032 strategy. Research focus areas include molecular cell biology, neuroscience, cardiovascular medicine, and oncology, with active collaborations including joint development of expansion microscopy with MIT (announced 2026-06-23) and a Phase I MVA-MERS-S vaccine trial with DZIF and CEPI (published in Nature Communications, 2026-01-26).

The technical platform spans clinical care, research infrastructure, and education. Notable proprietary capabilities include a privacy-preserving federated learning framework using pre-trained CT foundation models for multi-center lymph node metastasis detection in pancreatic cancer (2026-04-09), and the STÄPS simulation training center for medical education using standardized patients and OSCE examinations. The Studienzentrum provides IT, biometry, project management, and vigilance services to support clinical trials. Revenue is generated primarily through inpatient and outpatient care billed under the German DRG (Diagnosis Related Groups) system and statutory health insurance (GKV) frameworks, supplemented by research grants (Drittmittel), state subsidies, and teaching block funding. The go-to-market is direct-to-patient, with a recently formalized 'Ärzte & Zuweiser' (referring physicians) channel and regional patient transfer services. A major Neubau (new construction) project is currently underway as part of the UMGestalten 2032 modernization initiative, and the institution hosts the iSLS 2027 international conference.

University Medicine Göttingen firmographics

Firmographics
Name
University Medicine Göttingen
Legal name
Universitätsmedizin Göttingen
Website
https://umg.eu
Company type
Private
Founded year
1732
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Universitätsmedizin Göttingen is a public university medical center combining patient care, biomedical research, and medical education across 61 clinics with 1,600 beds, serving 325,000 inpatients and outpatients annually in southern Lower Saxony, Germany.
Ownership category
akta.pro rank

University Medicine Göttingen industry classification

Industry
Product category
University Hospital and Academic Medical Center
NAICS
General Medical and Surgical Hospitals (6221), Offices of Physicians (62111)
SIC
Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro primary industry
Ambulatory Specialty Clinics (Multi-Specialty & Single-Specialty) (HLAFABAA)
akta.pro secondary industry
Oncology & Cancer Specialty Hospitals (HLAFAHAC)

Keywords

  • University medical center
  • Inpatient healthcare services
  • Medical research
  • Clinical trials
  • Medical education training

Where University Medicine Göttingen is headquartered

Location

Headquarters

HQ city
Göttingen
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

University Medicine Göttingen business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

  1. Hospital Services Revenue: University medical center providing comprehensive healthcare services to patients, funded through statutory health insurance (GKV) and private insurance systems in Germany. Revenue generated from inpatient and outpatient medical treatments, procedures, and specialized clinical services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

University Medicine Göttingen product offering

Product offering

Core offering

Universitätsmedizin Göttingen (UMG) operates as an academic medical center combining inpatient and outpatient clinical care, biomedical research, and medical education under a single institution. It runs 61 clinics, institutes, and departments with 1,600 beds, treating approximately 55,000 inpatients and 270,000 outpatients annually. Core clinical offerings include specialized treatments across oncology, cardiovascular medicine, neurosciences, and molecular cell biology, complemented by research focus areas and the STÄPS simulation-based medical training facility.

Product overview

The Universitätsmedizin Göttingen (UMG) operates as an academic medical center combining clinical healthcare services, medical research, and education under one institution. The organization encompasses approximately 61 clinics, institutes, and departments with 1,600 beds, serving 55,000 inpatients and 270,000 outpatients annually. Key operational units include research focus areas (Molecular Cell Biology, Neuroscience, Cardiovascular Medicine, Oncology), a Studienzentrum (Study Center) providing IT, biometry, project management and vigilance services, and STÄPS as a dedicated simulation-based medical training facility.

Differentiator

Problem solved

Functional benefit

Brands

  • Medizincampus Wolfsburg (MCW): Medical campus location in Wolfsburg for medical education
  • STÄPS - Studentisches Trainingszentrum Ärztlicher Praxis und Simulation
  • Lehrhospital
  • Alzheimer-Stiftung
  • UMG add on

Products and services

  • Inpatient Hospital Services Comprehensive inpatient medical care across 61 clinics, institutes, and departments with 1,600 beds, serving approximately 55,000 inpatients per year. Includes specialized treatment across oncology, cardiovascular medicine, neurosciences, and molecular cell biology.
  • Outpatient Clinics and Ambulatory Care Outpatient medical services including consultations, specialized ambulances (Sprechstunden), and ambulatory treatments serving approximately 270,000 outpatients per year.
  • Emergency Medicine Services Emergency medical services including the ARDS/ECMO Center for intensive care and specialized emergency treatments for patients in southern Lower Saxony.
  • STÄPS Medical Simulation Training Student training center for medical practice and simulation where medical students practice clinical skills using simulated patients (Simulationspersonen) in role-play exercises and OSCE examinations (Objective Structured Clinical Examination).
  • Clinical Trials and Research Services Clinical trial services including IT/prozessmanagement, biometry/datenmanagement, project management, vigilance, and on-site management/study secretariats provided through the Studienzentrum (Study Center).
  • Medical Degree Programs Comprehensive medical education programs including the Medizincampus Wolfsburg (MCW) campus location for medical education, the Lehrhospital teaching hospital component, and continuing education programs.

Companies that use University Medicine Göttingen

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

University Medicine Göttingen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

University Medicine Göttingen partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Massachusetts Institute of Technology (MIT)coreStrategic or Co-development Partner · 23 June 2026Joint development of expansion microscopy technique that enlarges biological samples by 1,000-fold in each dimension. The technique enables amino acid visualization using conventional light microscopes, making high-resolution protein imaging more accessible without expensive cryo-EM or X-ray crystallography equipment.
  • Multi-center Research NetworkcoreStrategic or Co-development Partner · 9 April 2026Multi-center retrospective study on federated CT foundation models for privacy-preserving lymph node metastasis detection in pancreatic cancer, involving multiple institutions to improve diagnostic accuracy while protecting patient data.
  • German Center for Infection Research (DZIF)coreStrategic or Co-development Partner · 26 January 2026DZIF conducted a phase I clinical trial for the MVA-MERS-S vaccine candidate showing stable and functional immune response persisting at least 24 months after vaccination. Study funded by DZIF and CEPI, published in Nature Communications. This represents a major pandemic preparedness research collaboration.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

University Medicine Göttingen competitors and assessment

Company assessment

Direct peers

  • Universitätsklinikum Freiburg: Multi-specialty German university hospital with a similar combination of oncology, cardiovascular, and neuroscience research priorities. Comparable academic medical center governance model under a public-law structure.
  • Universitätsklinikum Köln: Large German university hospital of comparable scale (~1,500 beds) and research breadth. Direct comparable in size, public funding model, and translational research intensity.
  • Universitätsklinikum Heidelberg: Major German university hospital with strong translational research and one of the country's leading oncology programs. Closely comparable to UMG in research intensity, NCI-style comprehensive cancer center positioning, and specialty research breadth.
  • Universitätsklinikum Essen: German university hospital with notable oncology and transplant programs, comparable in academic structure and multi-specialty care delivery. Relevant reference for UMG's oncology and surgical specialty positioning.
  • LMU Klinikum München: Large multi-specialty academic medical center affiliated with Ludwig-Maximilians-Universität. Comparable to UMG in size, multi-specialty depth, and integration of research and patient care under a single university umbrella.
  • Universitätsklinikum Tübingen: German university hospital with strong programs in oncology, neuroscience, and infectious disease, overlapping with UMG's research focus areas. Comparable academic medical center structure and translational research orientation.
  • Medizinische Hochschule Hannover (MHH): Independent medical university with university hospital of comparable size to UMG (~1,500 beds). Comparable scale, regional role, and research focus areas, including transplantation and immunology.
  • Universitätsklinikum Hamburg-Eppendorf (UKE): Comparable-scale German university hospital (~1,700+ beds, ~10,000 staff) with research strengths in oncology, neuroscience, and cardiovascular medicine. Directly comparable operating model, bed count, and research portfolio to UMG.
  • Charité – Universitätsmedizin Berlin: Largest German university hospital with a comparable three-pillar model of research, teaching, and patient care. Operates at significantly larger scale (~3,000 beds) and is the most direct reference peer for UMG's academic medical center operating model.

Regional players

  • Universitätsspital Basel: Comparable Swiss university hospital with multi-specialty academic medical center structure and translational research orientation. Operates in a different national healthcare system (Swiss DRG) but is structurally and functionally analogous to UMG.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

University Medicine Göttingen social profiles

Digital presence

University Medicine Göttingen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

University Medicine Göttingen leadership team

Management profile

Number of profiles

Profiles4 records

University Medicine Göttingen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

University Medicine Göttingen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about University Medicine Göttingen

What does University Medicine Göttingen do?

Universitätsmedizin Göttingen (UMG) operates as an academic medical center combining inpatient and outpatient clinical care, biomedical research, and medical education under a single institution. It runs 61 clinics, institutes, and departments with 1,600 beds, treating approximately 55,000 inpatients and 270,000 outpatients annually. Core clinical offerings include specialized treatments across oncology, cardiovascular medicine, neurosciences, and molecular cell biology, complemented by research focus areas and the STÄPS simulation-based medical training facility.

Is University Medicine Göttingen a public or private company?

University Medicine Göttingen is a private company. It is classified as state government owned and is currently operating.

When was University Medicine Göttingen founded?

University Medicine Göttingen was founded in 1732. It employs 1,001 to 5,000 people.

Where is University Medicine Göttingen based?

University Medicine Göttingen is headquartered in Göttingen, Germany, in the Europe region.

How does University Medicine Göttingen make money?

One revenue line is on record: hospital Services Revenue.

Who are University Medicine Göttingen's main competitors?

Direct peers on record are Universitätsklinikum Freiburg, Universitätsklinikum Köln, Universitätsklinikum Heidelberg, Universitätsklinikum Essen, LMU Klinikum München, Universitätsklinikum Tübingen, Medizinische Hochschule Hannover (MHH), Universitätsklinikum Hamburg-Eppendorf (UKE) and Charité – Universitätsmedizin Berlin. Universitätsspital Basel is listed as a regional player.

Does University Medicine Göttingen have an API?

No public API is recorded for University Medicine Göttingen.

What industry is University Medicine Göttingen in?

University Medicine Göttingen's product category is University Hospital and Academic Medical Center. Its primary akta.pro industry code is HLAFABAA, Ambulatory Specialty Clinics (Multi-Specialty & Single-Specialty), with a secondary code of HLAFAHAC, Oncology & Cancer Specialty Hospitals. Its NAICS code is 6221 and its SIC code is 8060.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AdvfnUniversity Medical Center Göttingen Takes a New Approach to the Use of Clinical DataUniversity Medical Center Göttingen became the first German and EU hospital to adopt MDClone's ADAMS platform, building on its existing data integration center. The platform enables secure, independent exploration of longitudinal clinical data and generates synthetic datasets for research and AI testing.PR NewswireUniversity Medical Center Göttingen Takes a New Approach to the Use of Clinical DataUniversity Medical Center Göttingen became the first German and EU hospital to adopt MDClone's ADAMS data utilization platform, building on its existing UMG-MeDIC data integration center. The platform enables secure, independent exploration of longitudinal clinical data and generates synthetic datasets for research and AI testing. It aims to improve data accessibility for research, patient care, and quality management.News-MedicalNew model creates a realistic picture of how vesicles support synaptic transmissionResearchers from the Okinawa Institute of Science and Technology (OIST) and the University Medical Center Göttingen (UMG) published a study in Science Advances detailing a new computational model of the synaptic vesicle cycle. The model reveals how vesicles support synaptic transmission at high stimulation frequencies, identifying key proteins like synapsin-1 and tomosyn-1 that regulate neurotransmitter release. This advancement provides deeper insights into brain function and potential therapeutic targets for neurological diseases.National Center for Biotechnology InformationAccelerating the Front End of Medicine: Three Digital Use Cases and HCI ImplicationsA research paper from the University Medical Centers of M\u00fcnster and G\u00f6ttingen, Germany, presents three digital application case studies covering emergency medicine, patient administration and AI-supported cancer diagnosis, framed as the "front end of medicine" before treatment. The authors derive HCI criteria of speed, accuracy, modularity and individuality, and report 93.5% accuracy for automated feature extraction and 97.5% or higher for individual features.PR NewswireBiondVax to Present at this week's Biomed Israel ConferenceBiondVax Pharmaceuticals Ltd. announced it will present at the 20th Biomed Israel Conference in Tel Aviv, Israel, on May 12, 2022, with Chief Scientific Officer Dr. Tamar Ben-Yedidia delivering the presentation. The presentation will focus on the company's development of nanosized antibodies (NanoAbs), being created in collaboration with the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen in Germany, targeting diseases including asthma, psoriasis, psoriatic arthritis, and macular degeneration. The announcement is a routine investor relations activity inviting meeting requests from attending investors.PR NewswireBiondVax to host analyst and investor webinar on April 4thBiondVax Pharmaceuticals Ltd. announced it will host an analyst and investor webinar on April 4, 2022, to discuss recent business updates including its nanosized antibody (NanoAb) pipeline development, in-house manufacturing preparations, and European Investment Bank loan restructuring negotiations. The webinar will cover the company's collaboration with the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen in Germany, preparations at its GMP biologics manufacturing facility in Jerusalem, and FY'21 financial results.PR NewswireBiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateBiondVax Pharmaceuticals Ltd. published its fourth quarter and full year 2021 financial results, reporting total operating expenses of NIS 34.8 million ($11.2 million) compared with NIS 68.8 million in 2020, with cash position improving to NIS 54 million from NIS 9.4 million following secondary offerings. The company signed an exclusive license agreement in December 2021 with the Max Planck Institute and University Medical Center Göttingen for COVID-19 NanoAbs therapy, followed by a broader collaboration agreement in March 2022 for NanoAb pipeline therapies addressing asthma, psoriasis, psoriatic arthritis, and macular degeneration. The European Investment Bank agreed to extend its loan maturity to December 2027, providing continued financial support for BiondVax's strategic turnaround plans.BenzingaBVXV: Building a Pipeline of VHH Antibody Drug Candidates…BiondVax Pharmaceuticals Ltd. signed definitive agreements with the Max Planck Institute for Biophysical Chemistry and University Medical Center Göttingen (UMG) in Germany for exclusive worldwide development and commercialization of nano-sized (VHH) antibody candidates targeting COVID-19, with proof-of-concept animal data anticipated in 2022 and clinical trials expected to begin in 2023. The company also executed a term sheet for a broader five-year collaboration to build a VHH antibody pipeline targeting additional diseases including psoriasis, psoriatic arthritis, asthma, and macular degeneration, with BiondVax holding an exclusive option for worldwide licenses. On December 27, 2021, BiondVax announced an underwritten public offering of 3,813,560 ADSs at $2.36 per ADS, raising approximately $9.0 million in gross proceeds.BenzingaWhy BiondVax Shares Are Soaring TodayBiondVax Pharmaceuticals Ltd announced it signed definitive agreements with the Max Planck Society and University Medical Center Göttingen for the development and commercialization of nanosized COVID-19 antibody therapies, with a broader collaboration covering additional disease indications expected next month. The company stated that in laboratory testing, these nanoantibodies demonstrated superior affinity by neutralizing SARS-CoV-2 at drug concentrations approximately 100 times lower than currently available monoclonal antibodies. BiondVax, previously focused on flu vaccine commercialization and manufacturing, sees this as an expansion into a potential superior therapeutic platform for COVID-19.PR NewswireBiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical CBiondVax Pharmaceuticals has signed definitive agreements with the Max Planck Institute of Biophysical Chemistry and the University Medical Center Göttingen in Germany, securing an exclusive worldwide license to develop and commercialize innovative nanosized COVID-19 antibodies (NanoAbs). The NanoAbs demonstrate approximately 100 times stronger viral neutralization against SARS-CoV-2 compared to currently available monoclonal antibodies and remain stable at 95°C, potentially enabling convenient inhalation administration. The company plans to initiate preclinical studies in 2022 with initial human clinical trial results expected in 2023, while also expanding the collaboration to address other therapeutic areas including psoriasis, asthma, macular degeneration, and psoriatic arthritis.